Policy recommendations for chlorproguanil-dapsone for treating malaria requires additional trials that follow up participants for longer and examine adverse effects more carefully. Chlorproguanil-dapsone is a new combination of existing drugs and being marketed for treating malaria. Trials to date show some evidence of benefit in cure rates 14 days after the treatment is started, but there is no obvious advantage demonstrated to date over sulfadoxine-pyrimethamine. In addition, there is some evidence of more frequent serious adverse effects with chlorproguanil-dapsone.
The Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD004387. DOI: 10.1002/14651858.CD004387.pub2.